JNJ-77242113
janssen,ventyx,protagonist therapeutics
['derm', 'psoriasis', '$jnj', 'protagonist ', '$ptgx', '$vtyx']
jmp securities raised pt $ptgx $35 was $28/outperform
after protagonist therapeutics' detailed phase 2b data at the world congress of dermatology that supports jnj-2113 as the most efficacious oral agent in development for psoriasis (pso). $jnj $vtyx #wcd2023
#wcd2023singapore 